C
Christine M. Pierce Campbell
Researcher at University of Michigan
Publications - 32
Citations - 1213
Christine M. Pierce Campbell is an academic researcher from University of Michigan. The author has contributed to research in topics: HPV infection & Papillomaviridae. The author has an hindex of 14, co-authored 29 publications receiving 1069 citations. Previous affiliations of Christine M. Pierce Campbell include Moffitt Cancer Center.
Papers
More filters
Journal ArticleDOI
Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study
Aimée R. Kreimer,Christine M. Pierce Campbell,Hui-Yi Lin,William J. Fulp,Mary R. Papenfuss,Martha Abrahamsen,Allan Hildesheim,Luisa L. Villa,Jorge Salmerón,Eduardo Lazcano-Ponce,Anna R. Giuliano +10 more
TL;DR: Acquisition of oral oncogenic HPV was significantly associated with smoking and not being married or cohabiting, but was similar across countries, age groups, and reported sexual behaviours.
Journal ArticleDOI
EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus‐related cancer incidence by gender and anatomic site of infection
Anna R. Giuliano,Alan G. Nyitray,Aimée R. Kreimer,Christine M. Pierce Campbell,Marc T. Goodman,Staci L. Sudenga,Joseph Monsonego,Silvia Franceschi +7 more
TL;DR: In this paper, differences in HPV-related cancer and infection burden by gender and anatomic site are reviewed, with nearly 100% of cervical, 88% of anal, and <50% of lower genital tract and oropharyngeal cancers attributable to HPV.
Journal ArticleDOI
Human Papillomavirus (HPV) L1 Serum Antibodies and the Risk of Subsequent Oral HPV Acquisition in Men: The HIM Study
Christine M. Pierce Campbell,Raphael P. Viscidi,B. Nelson Torres,Hui-Yi Lin,William J. Fulp,Martha Abrahamsen,Eduardo Lazcano-Ponce,Luisa L. Villa,Aimée R. Kreimer,Anna R. Giuliano +9 more
TL;DR: Oral rinses for HPV DNA and baseline sera for HPV-6, -11, -16, and -18 L1 antibodies and Cox models revealed that men with circulating antibodies to HPV- 6, - 11, - 16, or -18 were not less likely to acquire type-specific oral HPV than men without antibodies.
Journal ArticleDOI
Prevention of Invasive Cervical Cancer in the United States: Past, Present, and Future
TL;DR: Decreasing the burden of HPV infection and HPV-related diseases in the United States will require greater dissemination of the HPV vaccine to adolescents and young adults, along with successful implementation of revised ICC screening guidelines that incorporate HPV and cytology cotesting.
Journal ArticleDOI
Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study.
Staci L. Sudenga,Donna J. Ingles,Christine M. Pierce Campbell,Hui-Yi Lin,William J. Fulp,Jane L. Messina,Mark H. Stoler,Martha Abrahamsen,Luisa L. Villa,Eduardo Lazcano-Ponce,Anna R. Giuliano +10 more
TL;DR: Most EGLs develop following infection with HPV 6, 11, or 16, all of which could be prevented with the 4-valent HPV vaccine, according to a prospective analysis nested within the HPV Infection in Men study.